New hope for rare, aggressive cancer: experimental drug combo enters human trials
NCT ID NCT05019716
Summary
This study is testing a new oral drug, ZEN003694, in combination with standard chemotherapy for people with advanced NUT carcinoma, a rare and aggressive cancer. The main goals are to find a safe dose of the combination and see if it helps shrink tumors or slow the cancer's growth. Researchers will also collect blood and tissue samples to learn how the treatment affects the body and the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NUT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.